{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:58:01Z","timestamp":1790636281259,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:p>FCRL1 (Fc receptor\u2013like 1) is a cell-surface membrane protein belonging to FCRL family and is preferentially expressed on B cells. To evaluate FcRL1 as an immunotherapy target for B-cell malignancies, we prepared anti-FCRL1 mAbs without cross-reactivity to other FCRL family proteins and analyzed FCRL1 protein expression on malignant cells from patients and on B-cell lines. Frequent FCRL1 expression was observed by flow cytometry on 12 B-cell non-Hodgkin lymphoma (B-NHL) cell lines and many patient samples: 12 of 14 chronic lymphocytic leukemia (CLL), 7 of 7 follicular lymphoma (FL), 13 of 17 hairy cell leukemia (HCL), and 2 of 3 mantle cell lymphoma (MCL). Two recombinant immunotoxins, E3(Fv)-PE38 and E9(Fv)-PE38, were constructed. Both immunotoxins bound to FCRL1-positive cells with similar affinities (3.4 and 3.2 nM) and were cytotoxic to cell lines, but E9(Fv)-PE38 was 4- to 20-fold more cytotoxic than E3(Fv)-PE38. The concentrations that inhibited response by 50% (IC50s) of E9(Fv)-PE38 on 11 different FCRL1-positive cell lines ranged from 1.0 ng\/mL to 90 ng\/mL and correlated with the FCRL1 expression levels. Our results suggest that anti-FCRL1 immunotoxin E9(Fv)-PE38 exhibits remarkably specific cytotoxicity and merits further evaluation for the treatment of FCRL1-positive malignancies, including CLL, HCL, FL, MCL, and other B-NHL.<\/jats:p>","DOI":"10.1182\/blood-2007-07-102350","type":"journal-article","created":{"date-parts":[[2007,9,26]],"date-time":"2007-09-26T02:38:05Z","timestamp":1190774285000},"page":"338-343","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins"],"prefix":"10.1182","volume":"111","author":[{"given":"Xing","family":"Du","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ise","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111823370504500_B1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1146\/annurev.immunol.25.022106.141541","article-title":"Fc receptor-like molecules.","volume":"25","author":"Davis","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"2019111823370504500_B2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ni0506-431","article-title":"New nomenclature for Fc receptor-like molecules.","volume":"7","author":"Maltais","year":"2006","journal-title":"Nat Immunol"},{"key":"2019111823370504500_B3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.87.11.1","article-title":"Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies.","volume":"11","author":"Ise","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2019111823370504500_B4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.leu.2404445","article-title":"Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.","volume":"21","author":"Ise","year":"2007","journal-title":"Leukemia"},{"key":"2019111823370504500_B5","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia.","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"key":"2019111823370504500_B6","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-03-0750","article-title":"Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT).","volume":"102","author":"Falini","year":"2003","journal-title":"Blood"},{"key":"2019111823370504500_B7","first-page":"341","article-title":"Identification of outcome predictors in diffuse large B-cell lymphoma: immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue microarrays.","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"2019111823370504500_B8","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1182\/blood.V99.8.2662","article-title":"IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells.","volume":"99","author":"Miller","year":"2002","journal-title":"Blood"},{"key":"2019111823370504500_B9","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1073\/pnas.171308498","article-title":"Identification of a family of Fc receptor homologs with preferential B cell expression.","volume":"98","author":"Davis","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111823370504500_B10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2004-06-2344","article-title":"FcRH1: an activation coreceptor on human B cells.","volume":"105","author":"Leu","year":"2005","journal-title":"Blood"},{"key":"2019111823370504500_B11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer.","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2019111823370504500_B12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.med.58.070605.115320","article-title":"Immunotoxin treatment of cancer.","volume":"58","author":"Pastan","year":"2007","journal-title":"Annu Rev Med"},{"key":"2019111823370504500_B13","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.","volume":"18","author":"Kreitman","year":"2000","journal-title":"J Clin Oncol"},{"key":"2019111823370504500_B14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V90.5.2020","article-title":"Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.","volume":"90","author":"Mansfield","year":"1997","journal-title":"Blood"},{"key":"2019111823370504500_B15","first-page":"2345","article-title":"Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.","volume":"8","author":"Nagata","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2019111823370504500_B16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/CJI.0b013e318053ed8e","article-title":"New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.","volume":"30","author":"Du","year":"2007","journal-title":"J Immunother"},{"key":"2019111823370504500_B17","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy.","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2019111823370504500_B18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.","volume":"345","author":"Kreitman","year":"2001","journal-title":"N Engl J Med"},{"key":"2019111823370504500_B19","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.","volume":"23","author":"Kreitman","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111823370504500_B20","unstructured":"Genbank, NCBI database. Accessed June 12, 2006 http:\/\/www.ncbi.nlm.nih.gov\/Genbank\/index.html"},{"key":"2019111823370504500_B21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-1759(03)00192-3","article-title":"DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins.","volume":"280","author":"Nagata","year":"2003","journal-title":"J Immunol Methods"},{"key":"2019111823370504500_B22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/hyb.1991.10.369","article-title":"Preferential generation of monoclonal IgG-producing hybridomas by use of vesicular stomatitis virus-mediated cell fusion.","volume":"10","author":"Nagata","year":"1991","journal-title":"Hybridoma"},{"key":"2019111823370504500_B23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0022-1759(85)90044-4","article-title":"Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay.","volume":"77","author":"Friguet","year":"1985","journal-title":"J Immunol Methods"},{"key":"2019111823370504500_B24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jim.2004.06.009","article-title":"Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay.","volume":"292","author":"Nagata","year":"2004","journal-title":"J Immunol Methods"},{"key":"2019111823370504500_B25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cyto.b.20063","article-title":"Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow.","volume":"67","author":"Ahmad","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"key":"2019111823370504500_B26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/(SICI)1097-0320(19971015)30:5<236::AID-CYTO4>3.0.CO;2-F","article-title":"U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation.","volume":"30","author":"Borowitz","year":"1997","journal-title":"Cytometry"},{"key":"2019111823370504500_B27","first-page":"503","article-title":"Recombinant immunotoxins in the treatment of cancer.","volume":"248","author":"Pastan","year":"2004","journal-title":"Methods Mol Biol"},{"key":"2019111823370504500_B28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-065X.1998.tb01448.x","article-title":"Somatic hypermutation of immunoglobulin variable region genes: focus on follicular lymphoma and multiple myeloma.","volume":"162","author":"Kosmas","year":"1998","journal-title":"Immunol Rev"},{"key":"2019111823370504500_B29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0165-4608(02)00861-0","article-title":"Interphase cytogenetic characterization of aberrations in the long arm of chromosome 1 in B-cell lymphoid malignancies.","volume":"144","author":"Weng","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"2019111823370504500_B30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.10181","article-title":"Characterization of the recurrent translocation t(1;1)(p36.3;q21.1\u20132) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis.","volume":"36","author":"Lestou","year":"2003","journal-title":"Genes Chromosom Cancer"},{"key":"2019111823370504500_B31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/gcc.10022","article-title":"Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines.","volume":"33","author":"Sobol","year":"2002","journal-title":"Genes Chromosom Cancer"},{"key":"2019111823370504500_B32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1074-7613(01)00109-1","article-title":"IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy.","volume":"14","author":"Hatzivassiliou","year":"2001","journal-title":"Immunity"},{"key":"2019111823370504500_B33","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/1\/338\/1220165\/zh800108000338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/1\/338\/1220165\/zh800108000338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T04:00:15Z","timestamp":1708228815000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/1\/338\/107972\/FCRL1-on-chronic-lymphocytic-leukemia-hairy-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-07-102350","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}